Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma Inc (NQ: INZY )

4.490 +0.180 (+4.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inozyme Pharma Inc

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) 
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the Jefferies Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
From Inozyme Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.